Investors and big pharma companies are waking up to the potential of techbio companies after years of avoidance, say experts ...

The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.

As active pharmaceutical ingredients (APIs) and medicines become more complex and the demand for efficiency rises, drug ...

From exploring the wonders of plants as a curious teen to leading global initiatives at SCIEX, Gitte Barknowitz has carved ...

As clinical trials continue to evolve, next-generation mobile technologies and applications are at the forefront of ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

Jane Koo, head of regulatory affairs at CTMC, plays an important role in accelerating the development and commercialization ...

The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeutics’ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform.

The current status of the Biosecure Act is that it was passed ​ by the US House of Representatives on Sep 9, with a vote of ...

As active pharmaceutical ingredients (APIs) and medicines become more complex and the demand for efficiency rises, drug developers and manufacturers must adapt their strategies to keep pace with the ...

In today's regulatory landscape, ensuring data integrity is crucial for compliance and process visibility. How can ...

Months after divesting seven European sites, the Swedish contract development and manufacturing organisation (CDMO) Recipharm ...